World News Insights
1-3 Minute Gist
Support LyrArc
Reader contributions keep LyrArc open for everyone
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
Direct From the Editor / On Topics Vital to the Nation
Browse Articles or use Lyrarc's US patented "Groups" and "Links" for new insights. A Lyrarc Group of Articles on a topic gives insights into particular angles shown in the Group Title. A Lyrarc Link shows more specific insights for 2 articles.
Trillions to AI shrink Infrastructure and Reindustrialization Articles
LyrArc brings in selected articles from many of the world's top publications.
Articles are selected by experts and you can see the gist of the important articles.
LyrArc Article Gist
The new airport terminal for New Delhi, India, compares favorably with the airports in Hong Kong and Singapore. Bangalore and Hyderabad have new airports, and Mumbai is getting a new airport in 2012.
The new airport terminal for New Delhi, India, compares favorably with the airports in Hong Kong and Singapore. Bangalore and Hyderabad have new airports, and Mumbai is getting a new airport in 2012.
Read LyrArc gist ›
Original article 1 minute, gist 1 minute
Original article 1 minute, gist 1 minute
1
Links
7
Groups
LyrArc Article Gist
Dr Kevin Lee, a British neuroscientist, heads EpiNova, a 60 person unit within Glaxo's R&D department. Lee founded two biotech startups before joining Glaxo. The smaller units called Discovery Performance Units are Glaxo's way of creating biotech startup like units which it is hoped will produce better results. The 36 DPU's in Glaxo R&D are given 3 year budgets and flexibility to make their own decisions for drug research. The large bureaucracy, scientists not working across fields and an older mindset are seen as obstacles in the search for new drugs. EpiNova with its own logo operates in a a Glaxo facility, an hour north of London. Decisions are made faster, says EpiNova chemist Dr. Wilson, and the atmosphere is that of a startup willing to try new approaches quickly.
Dr Kevin Lee, a British neuroscientist, heads EpiNova, a 60 person unit within Glaxo's R&D department. Lee founded two biotech startups before joining Glaxo. The smaller units called Discovery Performance Units are Glaxo's way of creating biotech startup like units which it is hoped will produce better results. The 36 DPU's in Glaxo R&D are given 3 year budgets and flexibility to make their own decisions for drug research. The large bureaucracy, scientists not working across fields and an older mindset are seen as obstacles in the search for new drugs. EpiNova with its own logo operates in a a Glaxo facility, an hour north of London. Decisions are made faster, says EpiNova chemist Dr. Wilson, and the atmosphere is that of a startup willing to try new approaches quickly.
Support LyrArc
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Copyright © 2006 - 2026 Intelilinks LLC
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us